April 04, 2018
1 min read

CVS Health announces new home dialysis initiative

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CVS Health announced a new initiative focused on early identification of chronic kidney disease and the expansion of home dialysis to optimize care for patients.

“In dialysis today, there is an enormous unmet medical need with high levels of mortality, frequent hospitalizations and poor quality of life for affected patients,” Alan Lotvin, MD, executive vice president and head of CVS Specialty said in a company press release. “As we explored this area, it became clear that our enterprise assets – from our experience with complex patient home care through Coram, the breadth of our chronic disease management capabilities with CVS Specialty and Accordant, and our deep payer relationships at CVS Caremark – will enable us to create a unique value proposition to help reshape dialysis treatment”

According to the press release, CVS Health will approach the initiative in a staged approach with phases focused on early identification and patient education, followed by the development of a comprehensive home dialysis program for both hemodialysis and peritoneal dialysis. CVS Health will initiate a clinical trial to demonstrate a new home hemodialysis device in support of a planned FDA submission to obtain market clearance. The device has been designed to make home hemodialysis safe and simple, company officials said.

“CVS Health is uniquely positioned to build a solution that will enable us to identify and intervene earlier with patients to optimize the management of chronic kidney disease, while at the same time making home dialysis therapies a real option for more patients,” Bruce Culleton, MD, vice president and chief medical officer of CVS Specialty, said in the release.